Bremelanotide's Neurobiological Effects on Sexual Desire Explored in Hamsters

Hypoactive sexual desire disorder (HSDD) is a common condition characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. Bremelanotide, marketed as Vyleesi, is the first FDA-approved on-demand treatment for premenopausal women with acquired, generalized HSDD. While its efficacy is established, the precise neurobiological mechanisms underlying its effects on sexual behavior, particularly in relevant animal models, are not fully elucidated, and understanding these mechanisms could lead to more targeted therapies.

The administration of bremelanotide significantly enhanced sexual receptivity and proceptivity in female Syrian hamsters compared to controls. Hamsters treated with 1.0 mg/kg bremelanotide showed a 55% increase in lordosis quotient (p<0.001) and a 40% reduction in latency to display proceptive behaviors (p<0.01). > The most significant finding was a 2.8-fold increase in dopamine release in the nucleus accumbens (p<0.001) in the 1.0 mg/kg bremelanotide group, a brain region critical for reward and motivation, suggesting a direct impact on the brain's pleasure pathways. Furthermore, 0.5 mg/kg bremelanotide also demonstrated a notable 32% increase in solicitations (p<0.05), indicating a dose-dependent effect on sexual motivation. These behavioral changes were correlated with increased activity in melanocortin-4 receptor (MC4R) pathways, consistent with bremelanotide's known mechanism of action.